NASDAQ:IONSIonis Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Ionis Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $56.21 -0.23 (-0.41 %) (As of 05/29/2020 04:00 PM ET) Add Compare Share Today's Range$54.92Now: $56.21▼$57.0450-Day Range$50.81MA: $54.74▼$58.3852-Week Range$39.32Now: $56.21▼$73.09Volume1.32 million shsAverage Volume800,439 shsMarket Capitalization$7.83 billionP/E Ratio51.10Dividend YieldN/ABeta1.7 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. It is involved in developing neurology products that include IONIS-HTTRx for Huntington's diseases; and IONIS-SOD1Rx and IONIS-C9Rx for amyotrophic lateral sclerosis and IONIS-MAPTRx for Alzheimer's diseases. The company is also developing severe and rare disease products, such as WAYLIVRA, a treatment for familial chylomicronemia syndrome; WAYLIVRA, a treatment for familial partial lipodystrophy; AKCEA-TTR-LRx for transthyretin amyloidosis and IONIS-GHR-LRx for acromegaly; and IONIS-TMPRSS6-LRx for beta-thalassemia and iron toxicity, IONIS-PKKRx/IONIS-PKK-LRx for hereditary angioedema, and IONIS-ENAC-2.5Rx for cystic fibrosis. In addition, its cardio metabolic and renal drugs include AKCEA-ANGPTL3-LRx for cardio metabolic disorders, IONIS-FXIRx for clotting disorders, AKCEA-APO(a)-LRx and AKCEA-APOCIII-LRx for cardiovascular diseases, and IONIS-DGAT2Rx for nonalcoholic steatohepatitis; IONIS-AGT-LRX for the treatment of resistant hyper tension; and IONIS-FXI-LRx for clotting disorders and IONIS-AZ4-2.5-LRx for cardiovascular diseases. Further, the company develops products for oncology that include IONIS-AR-2.5Rx and danvatirsen for cancers; and IONIS-HBVRx and IONIS-HBV-LRx for hepatitis b virus infection, and IONIS-FB-LRx for compliment meditated disease, and IONIS-JBI1-2.5Rx for gastrointestinal autoimmune diseases. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.Read More Beat the Market (BTM) Rank™ 4.2 Analyst's Opinion Consensus RatingIonis Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.44, and is based on 8 buy ratings, 7 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $74.21, Ionis Pharmaceuticals has a potential upside of 32.0% from its current price of $56.21.Amount of Analyst CoverageIonis Pharmaceuticals has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.3 Community Rank Outperform VotesIonis Pharmaceuticals has received 623 “outperform” votes. (Add your “outperform” vote.)Underperform VotesIonis Pharmaceuticals has received 741 “underperform” votes. (Add your “underperform” vote.)Community SentimentIonis Pharmaceuticals has received 54.33% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Ionis Pharmaceuticals and other stocks. Vote “Outperform” if you believe IONS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe IONS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldIonis Pharmaceuticals does not currently pay a dividend.Dividend GrowthIonis Pharmaceuticals does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ionis Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,382,550.00 in company stock.Percentage Held by InsidersOnly 2.40% of the stock of Ionis Pharmaceuticals is held by insiders.Percentage Held by Institutions84.02% of the stock of Ionis Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Ionis Pharmaceuticals are expected to grow in the coming year, from ($0.48) to $0.06 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ionis Pharmaceuticals is 51.10, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 15.34.Price to Earnings Ratio vs. SectorThe P/E ratio of Ionis Pharmaceuticals is 51.10, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 24.89.Price to Book Value per Share RatioIonis Pharmaceuticals has a P/B Ratio of 4.99. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 4.2Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.63 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:IONS Previous Symbol CUSIP46433010 CIK874015 Webwww.ionispharma.com Phone760-931-9200Debt Debt-to-Equity Ratio0.51 Current Ratio9.91 Quick Ratio9.83Price-To-Earnings Trailing P/E Ratio51.10 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$1.12 billion Price / Sales6.97 Cash Flow$2.43 per share Price / Cash Flow23.13 Book Value$11.27 per share Price / Book4.99Profitability EPS (Most Recent Fiscal Year)$2.08 Net Income$303.26 million Net Margins16.79% Return on Equity12.50% Return on Assets6.41%Miscellaneous Employees737 Outstanding Shares139,320,000Market Cap$7.83 billion Next Earnings Date8/5/2020 (Estimated) OptionableOptionable NASDAQ:IONS Rates by TradingView Receive IONS News and Ratings via Email Sign-up to receive the latest news and ratings for IONS and its competitors with MarketBeat's FREE daily newsletter. Ionis Pharmaceuticals (NASDAQ:IONS) Frequently Asked Questions How has Ionis Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Ionis Pharmaceuticals' stock was trading at $49.14 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, IONS stock has increased by 14.4% and is now trading at $56.21. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Ionis Pharmaceuticals? 16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ionis Pharmaceuticals in the last year. There are currently 1 sell rating, 7 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Ionis Pharmaceuticals. When is Ionis Pharmaceuticals' next earnings date? Ionis Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Ionis Pharmaceuticals. How were Ionis Pharmaceuticals' earnings last quarter? Ionis Pharmaceuticals Inc (NASDAQ:IONS) announced its earnings results on Wednesday, May, 6th. The company reported ($0.35) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.12) by $0.23. The business had revenue of $133 million for the quarter, compared to the consensus estimate of $161.59 million. Ionis Pharmaceuticals had a net margin of 16.79% and a return on equity of 12.50%. The business's revenue was down 55.2% compared to the same quarter last year. During the same period last year, the firm earned $0.62 earnings per share. View Ionis Pharmaceuticals' earnings history. What price target have analysts set for IONS? 16 equities research analysts have issued 12 month target prices for Ionis Pharmaceuticals' shares. Their forecasts range from $51.00 to $120.00. On average, they anticipate Ionis Pharmaceuticals' share price to reach $74.21 in the next year. This suggests a possible upside of 32.0% from the stock's current price. View analysts' price targets for Ionis Pharmaceuticals. Has Ionis Pharmaceuticals been receiving favorable news coverage? Headlines about IONS stock have trended negative this week, according to InfoTrie Sentiment. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Ionis Pharmaceuticals earned a media sentiment score of -2.6 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutIonis Pharmaceuticals. Who are some of Ionis Pharmaceuticals' key competitors? Some companies that are related to Ionis Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU) and Exelixis (EXEL). View all competitors. What other stocks do shareholders of Ionis Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ionis Pharmaceuticals investors own include CA (CA), Micron Technology (MU), Alibaba Group (BABA), BlackRock (BLK), Gilead Sciences (GILD), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), NVIDIA (NVDA), Intercept Pharmaceuticals (ICPT) and Skyworks Solutions (SWKS). Who are Ionis Pharmaceuticals' key executives? Ionis Pharmaceuticals' management team includes the following people: Dr. Stanley T. Crooke, Founder, Chairman, CEO & Pres (Age 74)Dr. Brett P. Monia, Founder, COO, Sr. VP of Translational Medicine & Director (Age 58)Ms. Elizabeth L. Hougen, Sr. VP of Fin. & CFO (Age 57)Dr. Richard S. Geary, Sr. VP of Devel. (Age 61)Ms. B. Lynne Parshall, Sr. Strategic Advisor & Director (Age 65) What is Ionis Pharmaceuticals' stock symbol? Ionis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IONS." Who are Ionis Pharmaceuticals' major shareholders? Ionis Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (6.28%), BlackRock Inc. (5.86%), Clearbridge Investments LLC (5.77%), Wellington Management Group LLP (2.86%), Invesco Ltd. (1.68%) and Waddell & Reed Financial Inc. (1.55%). Company insiders that own Ionis Pharmaceuticals stock include B Lynne Parshall, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Frederick T Muto, Joseph H Wender, Joseph Klein III, Patrick R O'neil, Richard S Geary, Spencer R Berthelsen and Stanley T Crooke. View institutional ownership trends for Ionis Pharmaceuticals. Which major investors are selling Ionis Pharmaceuticals stock? IONS stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Bank of New York Mellon Corp, Raymond James & Associates, JPMorgan Chase & Co., BlackRock Inc., Deutsche Bank AG, Two Sigma Advisers LP, and Russell Investments Group Ltd.. Company insiders that have sold Ionis Pharmaceuticals company stock in the last year include Brett P Monia, Elizabeth L Hougen, Frederick T Muto, Joseph Klein III, Patrick R O'neil, Richard S Geary, Spencer R Berthelsen, and Stanley T Crooke. View insider buying and selling activity for Ionis Pharmaceuticals. Which major investors are buying Ionis Pharmaceuticals stock? IONS stock was acquired by a variety of institutional investors in the last quarter, including Rockefeller Capital Management L.P., Swiss National Bank, Clearbridge Investments LLC, Aviva PLC, Sector Gamma AS, Federated Hermes Inc., Trexquant Investment LP, and Geode Capital Management LLC. View insider buying and selling activity for Ionis Pharmaceuticals. How do I buy shares of Ionis Pharmaceuticals? Shares of IONS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Ionis Pharmaceuticals' stock price today? One share of IONS stock can currently be purchased for approximately $56.21. How big of a company is Ionis Pharmaceuticals? Ionis Pharmaceuticals has a market capitalization of $7.83 billion and generates $1.12 billion in revenue each year. The company earns $303.26 million in net income (profit) each year or $2.08 on an earnings per share basis. Ionis Pharmaceuticals employs 737 workers across the globe. What is Ionis Pharmaceuticals' official website? The official website for Ionis Pharmaceuticals is www.ionispharma.com. How can I contact Ionis Pharmaceuticals? Ionis Pharmaceuticals' mailing address is 2855 GAZELLE COURT, CARLSBAD CA, 92010. The company can be reached via phone at 760-931-9200. This page was last updated on 6/1/2020 by MarketBeat.com Staff
